Class & Mechanism — Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of medications used for the treatment of type 2 diabetes and obesity. It mimics the action of the incretin hormone GLP-1, which stimulates insulin secretion and suppresses glucagon secretion, thereby improving glycemic control. [1]
Research-documented benefits —
– Promotes significant weight loss in patients with type 2 diabetes (T2D) and non-diabetic individuals. [8]
– Reduces cardiovascular risk in patients with T2D. [13]
– Has been shown to potentially reduce the risk of adverse cardiovascular and renal outcomes. [13]
– Investigated for the treatment of nonalcoholic fatty liver disease (NASH) and in an oral formulation for the treatment of T2D. [1]
General-knowledge benefits —
– Reduces body weight through an effect to reduce energy intake. [1]
– Positively affects cardiovascular outcomes in individuals with T2D, although the precise mechanism is still being explored. [1]
Typical injectable protocol — Semaglutide is typically administered subcutaneously once weekly at a dose of 0.5 mg to 1 mg, depending on the indication and patient tolerance. [1]
Key risks / contraindications — Common side effects include gastrointestinal issues such as nausea and vomiting. It is not recommended for use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. [1]
Bottom line — Semaglutide is a potent GLP-1 receptor agonist used for the treatment of T2D and obesity, with potential benefits in cardiovascular and renal health.
References
- Antimicrobial Peptides and Human Disease
- Basal Insulin Glargine 100 U_mL Versus 300 U_mL in Type 2 Diabetes
- GLP-1 and the kidney_ from physiology to pharmacology and outcomes in diabetes
- Growth Hormone Secretagogues in Clinical Practice
- Handbook of Biologically Active Peptides
- Human trials exploring anti-aging medicines — Guarente, Leonard (author)
- Incretin-Based Therapies for Type 2 Diabetes
- Kosmetik für Ärzte und Apotheker
- Nutrition in Mental Health_ A Handbook
- Peptide Therapeutics_ Design and Development
- Peptides_ Chemistry and Biology, 2nd Edition
- Platelets
- Prodrugs_ Challenges and Rewards
- Super Agers An Evidence-Based Approach to Longevity — Eric Topol
- The AI Revolution in Medicine_ GPT-4 and Beyond
- The discovery and development of liraglutide and semaglutide